SAFETY, IMMUNOGENICITY AND IMPACT ON PARASITE MULTIPLICATION RATES OF THE CANDIDATE BLOOD-STAGE VACCINE AMA1-C1/ALHYDROGEL WITH THE NOVEL ADJUVANT CPG 7909 AGAINST BLOOD-STAGE MALARIA CHALLENGE IN HEALTHY MALARIA-NAIVE VOLUNTEERS

Eitemau Tebyg

• Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
  gan: Duncan, C, et al.
  Cyhoeddwyd: (2011)
• Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
  gan: Christopher J A Duncan, et al.
  Cyhoeddwyd: (2011-01-01)
• Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
  gan: Gregory E D Mullen, et al.
  Cyhoeddwyd: (2008-08-01)
• Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
  gan: Ruth D Ellis, et al.
  Cyhoeddwyd: (2012-01-01)
• Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
  gan: Ruth D Ellis, et al.
  Cyhoeddwyd: (2010-01-01)